Browse studies

Find your next paid study

668 recruiting studies matching your filters

Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor

Background: Chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) are diseases in which the body makes too many white blood cells that do not wo…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia

Estimated

~$10 – $5,625

National Heart, Lung, and Blood Institute (NHLBI)NCT07796373

Phase 3

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with n…

B Acute Lymphoblastic Leukemia

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT03150693

Blinded Reference Set for Multicancer Early Detection Blood Tests

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing …

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAnn Arbor Stage I Lymphoma+59 more

Phase 2

Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen…

Core Binding Factor Acute Myeloid Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06917911

Phase 1

Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-cell Acute Lymphoblastic Leukemia (B-ALL)

Background: B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene mutation that makes the disease hard to …

B-AllAcute Lymphoblastic Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07572136

Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation

Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with…

Graft-Versus-Host DiseaseGraft-versus-leukemiaDonor Apheresis

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT00001529

Phase 2

A Phase II Study Evaluating the Efficacy of Ruxolitinib in Patients With T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growt…

T-Cell Large Granular Lymphocyte Leukemia

Estimated

~$10 – $7,500

Jonathan BrammerNCT05592015

Phase 3

A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patients With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce…

HypogammaglobulinemiaBacterial InfectionsB-cell Chronic Lymphocytic Leukemia+2 more

Estimated

~$10 – $8,750

Grifols Therapeutics LLCNCT05645107

Phase 3

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04269902

Phase 1

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the …

Malignancy, HematologicNeoplasms, HematologicNeoplasms, Hematopoietic+8 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06904066

Phase 2

Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant

Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but…

Acute Myeloid LeukemiaMyeloproliferative NeoplasmMyelodysplastic Syndromes

Estimated

~$10 – $6,250

Stanford UniversityNCT07634536

Observational

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leukemia

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who ac…

B-AllAcute Lymphoblastic Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05621291